Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Emergency Surgery
Published in: World Journal of Emergency Surgery 1/2018

Open Access 01-12-2018 | Review

2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections

Authors: Massimo Sartelli, Xavier Guirao, Timothy C. Hardcastle, Yoram Kluger, Marja. A. Boermeester, Kemal Raşa, Luca Ansaloni, Federico Coccolini, Philippe Montravers, Fikri M. Abu-Zidan, Michele Bartoletti, Matteo Bassetti, Offir Ben-Ishay, Walter L. Biffl, Osvaldo Chiara, Massimo Chiarugi, Raul Coimbra, Francesco Giuseppe De Rosa, Belinda De Simone, Salomone Di Saverio, Maddalena Giannella, George Gkiokas, Vladimir Khokha, Francesco M. Labricciosa, Ari Leppäniemi, Andrey Litvin, Ernest E. Moore, Ionut Negoi, Leonardo Pagani, Maddalena Peghin, Edoardo Picetti, Tadeja Pintar, Guntars Pupelis, Ines Rubio-Perez, Boris Sakakushev, Helmut Segovia-Lohse, Gabriele Sganga, Vishal Shelat, Michael Sugrue, Antonio Tarasconi, Cristian Tranà, Jan Ulrych, Pierluigi Viale, Fausto Catena

Published in: World Journal of Emergency Surgery | Issue 1/2018

Login to get access

Abstract

Skin and soft-tissue infections (SSTIs) encompass a variety of pathological conditions that involve the skin and underlying subcutaneous tissue, fascia, or muscle, ranging from simple superficial infections to severe necrotizing infections. SSTIs are a frequent clinical problem in surgical departments. In order to clarify key issues in the management of SSTIs, a task force of experts met in Bertinoro, Italy, on June 28, 2018, for a specialist multidisciplinary consensus conference under the auspices of the World Society of Emergency Surgery (WSES) and the Surgical Infection Society Europe (SIS-E). The multifaceted nature of these infections has led to a collaboration among general and emergency surgeons, intensivists, and infectious disease specialists, who have shared these clinical practice recommendations.
Literature
1.
2.
3.
Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174–81.PubMedCrossRef
4.
Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med. 2007;74(Suppl 4):S21–8.PubMedCrossRef
5.
Napolitano LM. Severe soft tissue infections. Infect Dis Clin N Am. 2009;23:571–91.CrossRef
6.
Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Expert panel on managing skin and soft tissue infections. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(Suppl 1):i3–17.PubMedCrossRef
7.
May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, Eachempati SR. Surgical Infection Society. Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect. 2009;10:467–99.CrossRef
8.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:147–59.PubMedCrossRef
9.
10.
Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9:57.PubMedPubMedCentralCrossRef
11.
Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16:e288–303.PubMedCrossRef
12.
Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16:e276–87.PubMedCrossRef
13.
Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152:784–91.PubMedCrossRef
14.
Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606–8.PubMedCrossRef
15.
Nicks BA, Ayello EA, Woo K, Nitzki-George D, Sibbald RG. Acute wound management: revisiting the approach to assessment, irrigation, and closure considerations. Int J Emerg Med. 2010;3:399–407.PubMedPubMedCentralCrossRef
16.
Ovington L. Bacterial toxins and wound healing. Ostomy Wound Manage. 2003;49(7A Suppl):8–12.PubMed
17.
Sganga G, Tascini C, Sozio E, Carlini M, Chirletti P, Cortese F, et al. Focus on the prophylaxis, epidemiology and therapy of methicillin-resistant Staphylococcus aureus surgical site infections and a position paper on associated risk factors: the perspective of an Italian group of surgeons. World J Emerg Surg. 2016;11:267.CrossRef
18.
Wheadle WG. Risk factors for surgical site infection. Surg Infect. 2006;7(Suppl 1):S7–11.
19.
Owens P, McHugh S, Clarke-Moloney M, Healy D, Fitzpatrick F, McCormick P, et al. Improving surgical site infection prevention practices through a multifaceted educational intervention. Ir Med J. 2015;108:78–81.PubMed
20.
Romani L, Koroivueta J, Steer AC, Kama M, Kaldor JM, Wand H, et al. Scabies and impetigo prevalence and risk factors in Fiji: a national survey. PLoS Negl Trop Dis. 2015;9:e0003452.PubMedPubMedCentralCrossRef
21.
Bernard P, Jarlier V, Santerre-Henriksen A. Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections. Ann DermatolVenereol. 2008;135:13–9.
22.
Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29:243–8.PubMedCrossRef
23.
Tong SY, Varrone L, Chatfield MD, Beaman M, Giffard PM. Progressive increase in community-associated methicillin-resistant Staphylococcus aureus in indigenous populations in northern Australia from 1993 to 2012. Epidemiol Infect. 2015;143:1519–23.PubMedCrossRef
24.
Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23:1091–8.PubMedCrossRef
25.
Esposito S, Bassetti M, Borrè S, Bouza E, Dryden M, Fantoni M, et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother. 2011;23:251–62.PubMedCrossRef
26.
27.
Garau J, Ostermann H, Medina J, Ávila M, McBride K, Blasi F, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19:E377–85.PubMedCrossRef
28.
Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med. 1985;14:15–9.PubMedCrossRef
29.
Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg. 1977;64:264–6.PubMedCrossRef
30.
Rossolini GM, Stefani S. Aetiology, resistance and diagnostic techniques in skin and skin structure infections. Infez Med. 2009;17(Suppl. 4):18–29.PubMed
31.
32.
Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30:579–81.PubMedCrossRef
33.
Lloyd-Smith E, Kerr T, Hogg RS, Li K, Montaner JS, Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. HarmReduct J. 2005;2:24.
34.
Pollini RA, Gallardo M, Hasan S, Minuto J, Lozada R, Vera A, et al. High prevalence of abscesses and self-treatment among injection drug users in Tijuana, Mexico. Int J Infect Dis. 2010;14(Suppl 3):e117–22.PubMedCrossRef
35.
Khalil PN, Huber-Wagner S, Altheim S, Bürklein D, Siebeck M, Hallfeldt K, et al. Diagnostic and treatment options for skin and soft tissue abscesses in injecting drug users with consideration of the natural history and concomitant risk factors. Eur J Med Res. 2008;13:415–24.PubMed
36.
Brett MM, Hood J, Brazier JS, Duerden BI, Hahné SJ. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect. 2005;133:575–82.PubMedPubMedCentralCrossRef
37.
Spijkerman IJ, van Ameijden EJ, Mientjes GH, Coutinho RA, van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol. 1996;49:1149–54.PubMedCrossRef
38.
Gilchrist J, Sacks JJ, White D, Kresnow MJ. Dog bites: still a problem? Inj Prev. 2008;14:296–301.PubMedCrossRef
39.
40.
Weber DJ, Hansen AR. Infections resulting from animal bites. Infect Dis Clin North Am. 1991;5:663.PubMed
41.
42.
Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev. 2001;2:CD001738.
43.
Oehler R, Velez AP, Mizrachi M, Lamarche J, Gompf S. Bite-related and septic syndromes by cats and dogs. Lancet Infect Dis. 2009;9:439–47.PubMedCrossRef
44.
Jaindl M, Grünauer J, Platzer P, Endler G, Thallinger C, Leitgeb J, Kovar FM. The management of bite wounds in children—a retrospective analysis at a level I trauma centre. Injury. 2012;43:2117–21.PubMedCrossRef
45.
Evgeniou E, Markeson D, Iyer S, Armstrong A. The management of animal bites in the United Kingdom. Eplasty. 2013;13:e27.PubMedPubMedCentral
46.
Esposito S, Piccioli I, Semino M, Principi N. Dog and cat bite-associated infections in children. Eur J ClinMicrobiol Infect Dis. 2013;32:971–6.CrossRef
47.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.PubMedPubMedCentralCrossRef
48.
Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57:7–13.PubMedCrossRef
49.
Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61:976–94.PubMedCrossRef
50.
Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978–84.PubMedPubMedCentralCrossRef
51.
52.
Macmorran E, Harch S, Athan E, Lane S, Tong S, Crawford L, et al. The rise of methicillin resistant Staphylococcus aureus: now the dominant cause of skin and soft tissue infection in Central Australia. Epidemiol Infect. 2017;145:2817–26.PubMedCrossRef
53.
Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatori clinic. Antimicrob Agents Chemother. 2007;51:423–8.PubMedCrossRef
54.
Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, et al. Prospective randomized trial of empiric therapy with trimethoprim- sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:2628–30.PubMedPubMedCentralCrossRef
55.
Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. 2007;194:606–10.PubMedCrossRef
56.
Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700–5.PubMedCrossRef
57.
Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8:53–66.PubMedCrossRef
58.
Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199:804–16.PubMedCrossRef
59.
Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ. Linezolid versus vancomycin forskin and soft tissue infections. Cochrane Database Syst Rev. 2013;7:CD008056.
60.
Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother. 2008;62(Suppl 3):iii15–23.PubMed
61.
Bliziotis IA, Plessa E, Peppas G, Falagas ME. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis. Ann Pharmacother. 2010;44:97–106.PubMedCrossRef
62.
Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 1 investigators. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl4):iv41–51.PubMed
63.
Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 2 investigators. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53–65.PubMed
64.
Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of eftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641–50.PubMedCrossRef
65.
Chahine EB, Sucher AJ, Knutsen SD. Tedizolid: a new oxazolidinone antibiotic for skin and soft tissue infections. Consult Pharm. 2015;30:386–94.PubMedCrossRef
66.
McCool R, Gould IM, Eales J, Barata T, Arber M, Fleetwood K, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis. 2017;17:39.PubMedPubMedCentralCrossRef
67.
Bassetti M, Peghin M, Carnelutti A, Righi E. The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis. 2018;31:141–7.PubMed
68.
Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24:361–8.PubMedCrossRef
69.
Bassetti M, Eckmann C, Peghin M, Carnelutti A, Righi E. When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis. 2018;31(2):163–9.PubMed
70.
Howell GM, Rosengart MR. Necrotizing soft tissue infections. Surg Infect. 2011;12:185–90.CrossRef
71.
Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32:1535.PubMedCrossRef
72.
Bechar J, Sepehripour S, Hardwicke J, Filobbos G. Laboratory risk indicator for necrotising fasciitis (LRINEC) score for the assessment of early necrotising fasciitis: a systematic review of the literature. Ann R Coll Surg Engl. 2017;99:341–6.PubMedPubMedCentralCrossRef
73.
Fernando SM, Tran A, Cheng W, Rochwerg B, Kyeremanteng K, Seely AJE, et al. Necrotizing soft tissue infection: diagnostic accuracy of physical examination, imaging, and LRINEC score: a systematic review and meta-analysis. Ann Surg. 2018. [Epub ahead of print] 
74.
Marwick C, Broomhall J, McCowan C, Phillips G, Gonzalez-McQuire S, Akhras K, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother. 2011;66:387–97.PubMedCrossRef
75.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.PubMedPubMedCentralCrossRef
76.
Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg. 2014;51:344–62.PubMedPubMedCentralCrossRef
77.
78.
Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003 Aug;85-A(8):1454–60.CrossRef
79.
Sabbaj A, Jensen B, Browning MA, Ma OJ, Newgard CD. Soft tissue infections and emergency department disposition: predicting the need for inpatient admission. Acad Emerg Med. 2009;16:1290–7.PubMedCrossRef
80.
Lonergan S, Rodriguez RM, Schaulis M, Navaran P. A case series of patients with black tar heroin-associated necrotizing fasciitis. J Emerg Med. 2004;26:47–50.PubMedCrossRef
81.
Mongelluzzo J, Tu B, Grimes B, Ziyeh S, Fortman J, Neilson J, Rodriguez RM. Correlation of physical exam findings with fever in patients with skin and soft tissue infections. West J Emerg Med. 2017;18:398–402.PubMedPubMedCentralCrossRef
82.
Carratalà J, Rosón B, Fernández-Sabé N, Shaw E, del Rio O, Rivera A, Gudiol F. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis. 2003;22:151–7.PubMed
83.
El-Menyar A, Asim M, Mudali IN, Mekkodathil A, Latifi R, Al-Thani H. The laboratory risk indicator for necrotizing fasciitis (LRINEC) scoring: the diagnostic and potential prognostic role. Scand J Trauma Resusc Emerg Med. 2017;25:28.PubMedPubMedCentralCrossRef
84.
Corbin V, Vidal M, Beytout J, Laurichesse H, D’Incan M, Souteyrand P, Lesens O. Prognostic value of the LRINEC score (Laboratory Risk Indicator for Necrotizing Fasciitis) in soft tissue infections: a prospective study at Clermont-Ferrand University hospital. Ann Dermatol Venereol. 2010;137:5–11.PubMedCrossRef
85.
Citak M, Backhaus M, Tilkorn DJ, O’loughlin PF, Meindl R, Muhr G, Fehmer T. Necrotizing fasciitis in patients with spinal cord injury: an analysis of 25 patients. Spine (Phila Pa 1976). 2011;36:E1225–9.CrossRef
86.
Swain RA, Hatcher JC, Azadian BS, Soni N, De Souza B. A five-year review of necrotising fasciitis in a tertiary referral unit. Ann R Coll Surg Engl. 2013;95:57–60.PubMedPubMedCentralCrossRef
87.
Colak E, Ozlem N, Kucuk GO, Aktimur R, Kesmer S. Laboratory risk indicators for necrotizing fasciitis and associations with mortality. Turk J Emerg Med. 2016;14:15–9.PubMedPubMedCentralCrossRef
88.
Bozkurt O, Sen V, Demir O, Esen A. Evaluation of the utility of different scoring systems (FGSI, LRINEC and NLR) in the management of Fournier’s gangrene. Int Urol Nephrol. 2015;47:243–8.PubMedCrossRef
89.
Malghem J, Lecouvet FE, Omoumi P, Maldague BE, Vande Berg BC. Necrotizing fasciitis: contribution and limitations of diagnostic imaging. Joint Bone Spine. 2013;80:146–54.PubMedCrossRef
90.
Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007;38(Suppl 5):S19–26.PubMed
91.
Walshaw CF, Deans H. CT findings in necrotising fasciitis—a report of four cases. Clin Radiol. 1996;51:429–32.PubMedCrossRef
92.
Zacharias N, Velmahos GC, Salama A, Alam HB, de Moya M, King DR, Novelline RA. Diagnosis of necrotizing soft tissue infections by computed tomography. Arch Surg. 2010;145:452–5.PubMedCrossRef
93.
Kim KT, Kim YJ, Won Lee J, Kim YJ, Park SW, Lim MK, Suh CH. Can necrotizing infectious fasciitis be differentiated from nonnecrotizing infectious fasciitis with MR imaging? Radiology. 2011;259:816–24.PubMedCrossRef
94.
Yen ZS, Wang HP, Ma HM, Chen SC, Chen WJ. Ultrasonographic screening of clinically-suspected necrotizing fasciitis. Acad Emerg Med. 2002;9:1448–51.PubMedCrossRef
95.
Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J. 1997;90:1065–8.PubMedCrossRef
96.
Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis: the use of frozen-section biopsy. N Engl J Med. 1984;310:1689–93.PubMedCrossRef
97.
Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44:705–10.PubMedCrossRef
98.
Andreasen TJ, Green SD, Childers BJ. Massive infectious soft-tissue injury: diagnosis and management of necrotizing fasciitis and purpura fulminans. Plast Reconstr Surg. 2001;107:1025–35.PubMedCrossRef
99.
Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998;64:397–400 discussion 400-1.PubMed
100.
Kobayashi L, Konstantinidis A, Shackelford S, Chan LS, Talving P, Inaba K, Demetriades D. Necrotizing soft tissue infections: delayed surgical treatment is associated with increased number of surgical debridements and morbidity. J Trauma. 2011;71:1400–5.PubMedCrossRef
101.
Boyer A, Vargas F, Coste F, Saubusse E, Castaing Y, Gbikpi-Benissan G, et al. Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management. Intensive Care Med. 2009;35:847–53.PubMedCrossRef
102.
Chao WN, Tsai CF, Chang HR, Chan KS, Su CH, Lee YT, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg. 2013;206:32–9.PubMedCrossRef
103.
Okoye O, Talving P, Lam L, Smith J, Teixeira PG, Inaba K, et al. Timing of redébridement after initial source control impacts survival in necrotizing soft tissue infection. Am Surg. 2013;79:1081–5.PubMed
104.
Soh CR, Pietrobon R, Freiberger JJ, Chew ST, Rajgor D, Gandhi M, et al. Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States nationwide inpatient sample. Intensive Care Med. 2012;38:1143–51.PubMedCrossRef
105.
Eskes A, Vermeulen H, Lucas C, Ubbink DT. Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds. Cochrane Database Syst Rev. 2013;12:CD008059.
106.
Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40.PubMedCrossRef
107.
Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:851–7.PubMedCrossRef
108.
Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369–76.PubMedCrossRef
109.
Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis. 2017;64:877–85.PubMed
110.
Hua C, Bosc R, Sbidian E, De Prost N, Hughes C, Jabre P, et al. Interventions for necrotizing soft tissue infections in adults. Cochrane Database Syst Rev. 2018;5:CD011680.PubMed
111.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.PubMedCrossRef
112.
Smeets L, Bous A, Heymans O. Necrotizing fasciitis: case report and review of literature. Acta Chir Belg. 2007;107:29–36.PubMedCrossRef
113.
114.
Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol. 2011;9:e1001149.PubMedPubMedCentralCrossRef
115.
Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 2014;149:528–36.PubMedCrossRef
116.
Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. 2016;62:1009–17.PubMedCrossRef
117.
Coyle EA, Cha R, Rybak MJ. Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. Antimicrob Agents Chemother. 2003;47:1752–5.PubMedPubMedCentralCrossRef
118.
Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007;195:202–11.PubMedCrossRef
119.
Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014;59:358–65.PubMedCrossRef
120.
Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19:v–xxv 1–236.PubMedPubMedCentral
121.
Friederichs J, Hutter M, Hierholzer C, Novotny A, Friess H, Bühren V, Hungerer S. Procalcitonin ratio as a predictor of successful surgical treatment of severe necrotizing soft tissue infections. Am J Surg. 2013;206:368–73.PubMedCrossRef
122.
Ghnnam WM. Fournier’s gangrene in Mansoura Egypt: a review of 74 cases. J Postgrad Med. 2008;54:106–9.PubMedCrossRef
123.
Ynar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, Baspinar I. Fournier’s gangrene: risk factors and strategies for management. World J Surg. 2006;30:1750–4.CrossRef
124.
Morua AG, Lopez JA, Garcia JD, Montelongo RM, Guerra LS. Fournier’s gangrene: our experience in 5 years, bibliographic review and assessment of the Fournier’s gangrene severity index. Arch Esp Urol. 2009;62:532–40.PubMed
125.
McCloud JM, Doucas H, Scott AD, Jameson JS. Delayed presentation of life-threatening perineal sepsis following stapled haemorrhoidectomy: a case report. Ann R Coll Surg Engl. 2007;89:301–2.PubMedPubMedCentralCrossRef
126.
Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangrene severity index score. Urology. 2004;64:218–22.PubMedCrossRef
127.
Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A. Fournier’s gangrene: three years of experience with 20 patients and validity of the Fournier’s gangrene severity index score. Eur Urol. 2006;50:838–43.PubMedCrossRef
128.
Corman J, Moody J, Aronson W. Fournier’s gangrene in a modern surgical setting: improved survival with aggressive management. BJU Int. 1999;84:85–8.PubMedCrossRef
129.
Gelbard RB, Ferrada P, Yeh DD, Williams B, Loor M, Yon J, et al. Optimal timing of initial debridement for necrotizing soft tissue infection: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2018;85:208–14.PubMedCrossRef
130.
Bronder CS, Cowey A, Hill J. Delayed stoma formation in Fournier’s gangrene. Color Dis. 2004;6:518–20.CrossRef
131.
132.
Estrada O, Martinez I, Del Bas M, Salvans S, Hidalgo LA. Rectal diversion without colostomy in Fournier’s gangrene. Tech Coloproctol. 2009;13:157–9.PubMedCrossRef
133.
Orgill DP, Manders EK, Sumpio BE, Lee RC, Attinger CE, Gurtner GC, Ehrlich HP. The mechanisms of action of vacuum assisted closure: more to learn. Surgery. 2009;146:40–51.PubMedCrossRef
134.
Huang WS, Hsieh SC, Hsieh CS, Schoung JY, Huang T. Use of vacuum-assisted wound closure to manage limb wounds in patients suffering from acute necrotizing fasciitis. Asian J Surg. 2006;29:135–9.PubMedCrossRef
135.
Mulla ZD, Gibbs SG, Aronoff DM. Correlates of length of stay, cost of care, and mortality among patients hospitalized for necrotizing fasciitis. Epidemiol Infect. 2006;3:1–9.
136.
Emohare O, Kowal-Vern A, Wiley D, Latenser BA. Vacuum-assisted closure use in calciphylaxis. J Burn Care Rehabil. 2004;25:161–4.PubMedCrossRef
137.
Fitzmaurice M, Lawson D, Friedman H. A novel approach for the application of the vacuum-assisted closure device to the difficult anatomy. J Plast Reconstr Aesthet Surg. 2006;59:1249–50.PubMedCrossRef
138.
Hofmann P, Friess P, Findeisen M, Tomcik P. Case report of successful therapy of necrotizing fasciitis using a device of vacuum assisted closure. Zentralbl Chir. 2006;131(suppl 1):S72–4.PubMedCrossRef
139.
de Geus HR, van der Klooster JM. Vacuum-assisted closure in the treatment of large skin defects due to necrotizing fasciitis. Intensive Care Med. 2005;31:601.PubMedCrossRef
140.
Oczenski W, Waldenberger F, Nehrer G, Kneifel W, Swoboda H, Schwarz S, Fitzgerald RD. Vacuum-assisted closure for the treatment of cervical and mediastinal necrotizing fasciitis. J Cardiothorac Vasc Anesth. 2004;18:336–8.PubMedCrossRef
141.
Rozeboom AL, Steenvoorde P, Hartgrink HH, Jukema GN. Necrotising fasciitis of the leg following a simple pelvic fracture: case report and literature review. J Wound Care. 2006;15:117–20.PubMedCrossRef
142.
Nouraei SA, Hodgson EL, Malata CM. Cervicofacial necrotising fasciitis: management with neck dissection and topical negative pressure. J Wound Care. 2003;12:147–9.PubMedCrossRef
143.
Oetting P, Rau B, Schlag PM. Abdominal vacuum device with open abdomen. Chirurg. 2006;77:586 588–93.PubMedCrossRef
144.
Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg. 2008;95:685–92.PubMedCrossRef
145.
Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev. 2008;3:CD001898.
146.
Peinemann F, Sauerland S. Negative-pressure wound therapy: systematic review of randomized controlled trials. Dtsch Arztebl Int. 2011;108:381–9.PubMedPubMedCentral
147.
Cobb WS, Carbonell AM, Kalbaugh CL, Jones Y, Lokey JS. Infection risk of open placement of intraperitoneal composite mesh. Am Surg. 2009;75:762–7 discussion 767–8.PubMed
148.
Cevasco M, Itani KM. Ventral hernia repair with synthetic, composite, and biologic mesh: characteristics, indications, and infection profile. Surg Infect. 2012;13:209–15.CrossRef
149.
Bachman S, Ramshaw B. Prosthetic material in ventral hernia repair: how do I choose? Surg Clin North Am. 2013;2008:101–12.
150.
Rosen MJ, Krpata DM, Ermlich B, Blatnik JA. A 5-year clinical experience with single-staged repairs of infected and contaminated abdominal wall defects utilizing biologic mesh. Ann Surg. 2013;257:991–6.PubMedCrossRef
151.
Latifi R. Practical approaches to definitive reconstruction of complex abdominal wall defects. World J Surg. 2016;40:836–48.PubMedCrossRef
152.
Mavros MN, Athanasiou S, Alexiou VG, Mitsikostas PK, Peppas G, Falagas ME. Risk factors for mesh-related infections after hernia repair surgery: a meta-analysis of cohort studies. World J Surg. 2011;35:2389–98.PubMedCrossRef
153.
Bueno-Lledó J, Torregrosa-Gallud A, Sala-Hernandez A, Carbonell-Tatay F, Pastor PG, Diana SB, Hernández JI. Predictors of mesh infection and explantation after abdominal wall hernia repair. Am J Surg. 2017;213:50–7.PubMedCrossRef
154.
Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs. 2005;28:1062–8.PubMedCrossRef
155.
Pérez-Köhler B, Bayon Y, Bellón JM. Mesh infection and hernia repair: a review. Surg Infect. 2016;17:124–37.CrossRef
156.
Kathju S, Nistico L, Melton-Kreft R, Lasko LA, Stoodley P. Direct demonstration of bacterial biofilms on prosthetic mesh after ventral herniorrhaphy. Surg Infect. 2015;16:45–53.CrossRef
157.
Paton BL, Novitsky YW, Zerey M, Sing RF, Kercher KW, Heniford BT. Managementof infections of polytetrafluoroethylene-based mesh. Surg Infect (Larchmt). 2007;8:337–41.CrossRef
158.
Montgomery A, Kallinowski F, Köckerling F. Evidence for replacement of an infected synthetic by a biological mesh in abdominal wall hernia repair. Front Surg. 2016;2:67.PubMedPubMedCentralCrossRef
159.
Shubinets V, Carney MJ, Colen DL, Mirzabeigi MN, Weissler JM, Lanni MA, et al. Management of infected mesh after abdominal hernia repair: systematic review and single-institution experience. Ann Plast Surg. 2018;80:145–53.PubMed
160.
Atema JJ, de Vries FE, Boermeester MA. Systematic review and meta-analysis of the repair of potentially contaminated and contaminated abdominal wall defects. Am J Surg. 2016;212:982–95 e1.PubMedCrossRef
161.
Atema JJ, Furnée EJ, Maeda Y, Warusavitarne J, Tanis PJ, Bemelman WA, et al. Major complex abdominal wall repair in contaminated fields with use of a non-cross-linked biologic mesh: a dual-institutional experience. World J Surg. 2017;41:1993–9.PubMedPubMedCentralCrossRef
Metadata
Title
2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections
Authors
Massimo Sartelli
Xavier Guirao
Timothy C. Hardcastle
Yoram Kluger
Marja. A. Boermeester
Kemal Raşa
Luca Ansaloni
Federico Coccolini
Philippe Montravers
Fikri M. Abu-Zidan
Michele Bartoletti
Matteo Bassetti
Offir Ben-Ishay
Walter L. Biffl
Osvaldo Chiara
Massimo Chiarugi
Raul Coimbra
Francesco Giuseppe De Rosa
Belinda De Simone
Salomone Di Saverio
Maddalena Giannella
George Gkiokas
Vladimir Khokha
Francesco M. Labricciosa
Ari Leppäniemi
Andrey Litvin
Ernest E. Moore
Ionut Negoi
Leonardo Pagani
Maddalena Peghin
Edoardo Picetti
Tadeja Pintar
Guntars Pupelis
Ines Rubio-Perez
Boris Sakakushev
Helmut Segovia-Lohse
Gabriele Sganga
Vishal Shelat
Michael Sugrue
Antonio Tarasconi
Cristian Tranà
Jan Ulrych
Pierluigi Viale
Fausto Catena
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Emergency Surgery / Issue 1/2018
Electronic ISSN: 1749-7922
DOI
https://doi.org/10.1186/s13017-018-0219-9

Other articles of this Issue 1/2018

World Journal of Emergency Surgery 1/2018 Go to the issue

Research article

Casualties of peace: an analysis of casualties admitted to the intensive care unit during the negotiation of the comprehensive Colombian process of peace

Study protocol

Closed Or Open after Source Control Laparotomy for Severe Complicated Intra-Abdominal Sepsis (the COOL trial): study protocol for a randomized controlled trial

Research article

Is case triaging a useful tool for emergency surgeries? A review of 106 trauma surgery cases at a level 1 trauma center in South Africa

Review

The open abdomen in trauma and non-trauma patients: WSES guidelines

Review

2017 WSES guidelines for the management of iatrogenic colonoscopy perforation

Research article

Impact of initial temporary abdominal closure in damage control surgery: a retrospective analysis